CareDx, Inc. (CDNA) is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions with a dedication towards transplant patients. The company's headquarters are in South San Francisco, California, and it has been publicly traded on the NASDAQ stock exchange under the ticker symbol "CDNA" since 2014.
Being a global firm, CareDx, Inc. offers its products and services to patients, clinicians, and transplant centers worldwide. Some of the company's innovative products include AlloMap, AlloSure, and AlloCare. The company uses both proprietary next-generation sequencing procedures and genomics machine learning algorithms to have a more accurate understanding of organ health.
AlloMap is a clinically validated, non-invasive blood test that aids in monitoring heart transplant patients for rejection. AlloSure, on the other hand, is a non-invasive test that accurately measures the level of donor-derived cell-free DNA (dd-cfDNA) in organ transplant patients, particularly kidney transplants. This innovation helps to determine the health of the transplanted organ and possibly detect risk of rejection. Recently, CareDx launched AlloCare, a comprehensive mobile app which enables transplant patients to oversee their health right from the comfort of their homes.
Notably, CDNA has adopted a patient-focused approach by continuously involving patients even after they undergo successful transplant surgeries. The company believes this to be a transformative strategy that sets them apart from other precision medicine companies. Importantly, through continuous follow-up and monitoring, CareDx ensures that patients receive the necessary care post transplantation, significantly reducing the rate of organ rejection.
Revenue-wise, CareDx, Inc. has demonstrated consistent growth over the last few years. The success is largely owed to its innovation, market leadership, and robust transplant ecosystem. As a forward-thinking company, CareDx continues to invest in research and development and collaborate with leading medical research institutions and organizations, thus consistently maintaining its role as a pioneer in the field of transplant medicine. The company's dedication to advancing precision medicine for transplant patients underscores its commitment to enhancing healthcare systems globally.
Highlighted for its exceptional strategic management and innovative breakthroughs, CareDx is certainly a noteworthy player in precision medicine. Its pioneering contributions in the medical field have not only revolutionized patient care in transplantation but also made a significant impact on global healthcare. As the company continues to optimize organ transplant care through its state-of-the-art solutions, CareDx is indeed contributing to shaping the future of precision medicine.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
The Centers for Medicare & Medicaid Services (CMS) plans to adjust its 2027 clinical laboratory fee schedule to align with private sector rates, aiming to save $1 billion annually. This change impacts diagnostics companies differently: BillionToOne sees favorable reimbursement updates for its oncology test and mixed results for its prenatal segment, while CareDx receives favorable updates for its core organ transplant portfolio, with key tests largely unaffected or seeing modest increases.
CareDx Inc (CDNA) shares recently rose 4.0%, bringing its current price to $56.49, significantly above its 52-week low. Despite this strong performance, GuruFocus assesses the stock as significantly overvalued with a GF Value™ of $25.41, a P/E ratio much higher than its historical median, and substantial insider selling. The company holds an above-average GF Score™ of 65/100, though its valuation and profitability scores are low.
Canaccord Genuity has initiated coverage on CareDx (CDNA) with a "Buy" rating and a price target of $65.00, despite GuruFocus indicating the stock is significantly overvalued at its current price of $48.77. The company, focused on precision medicine for transplant patients, shows strengths in financial stability and growth but weaknesses in valuation and has seen considerable insider selling. Investors are advised to exercise caution due to the overvaluation and mixed insider sentiment.
CareDx (CDNA) has seen significant share price appreciation recently, with strong short-term and long-term gains. Despite this rally, Simply Wall St's analysis suggests the stock could still be 10.2% undervalued, with a fair value of $52.33 compared to its current price of $46.99. However, the article also notes a high P/E ratio relative to the industry and fair value, raising questions about valuation risk.
Zacks.com has identified five top-ranked, high-efficiency stocks expected to deliver strong returns: CareDx, Healthcare Services Group, Forum Energy Technologies, Amneal Pharmaceuticals, and Caterpillar. These companies were selected based on key efficiency ratios such as Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin, which indicate strong resource management and profitability potential. Each company has also demonstrated significant average four-quarter earnings surprises.